» Articles » PMID: 36977145

Natural History of Hepatosplenic Schistosomiasis (HSS) Non-Cirrhotic Portal Hypertension (NCPH): Influence of Gastrointestinal Bleeding and Decompensation in Prognosis

Overview
Date 2023 Mar 28
PMID 36977145
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatosplenic schistosomiasis (HSS) is a peculiar form of non-cirrhotic portal hypertension (NCPH). Although HSS patients present normal hepatic function, some evolve signs of hepatocellular failure and features of decompensated cirrhosis. The natural history of HSS-NCPH is unknown.

Methods: A retrospective study was conducted that evaluated patients who fulfilled clinical-laboratorial criteria for HSS.

Results: A total of 105 patients were included. Eleven patients already presented with decompensated disease and had lower transplant-free survival at 5 years than those without (61% vs. 95%, = 0.015). Among 94 patients without prior decompensation, the median follow-up was 62 months and 44% of them had varicose bleeding (two or more episodes in 27%). Twenty-one patients presented at least one episode of decompensation (10-year probability 38%). Upon multivariate analysis, varicose bleeding and higher bilirubin levels were associated with decompensation. The 10-year probability of survival was 87%. Development of decompensation and age were predictive of mortality.

Conclusion: HSS is characterized by multiple episodes of GI bleeding, a high probability of decompensation and reduced survival at the end of the first decade. Decompensation is more common in patients with varicose esophageal bleeding and is associated with lower survival.

Citing Articles

Porto Sinusoidal Vascular Disorder: A Case Report.

Abdullahi N, Ahmed M, Yusuf M, Warsame H Int Med Case Rep J. 2025; 18:289-293.

PMID: 40046239 PMC: 11881601. DOI: 10.2147/IMCRJ.S502206.


Survival of patients with hepatopulmonary syndrome related to cirrhotic and non-cirrhotic (schistosomiasis) portal hypertension.

Rolim M, Farsoun L, Luna C, Markman-Filho B, Querette P, Lopes E World J Hepatol. 2025; 17(2):99134.

PMID: 40027571 PMC: 11866160. DOI: 10.4254/wjh.v17.i2.99134.

References
1.
Martins-Melo F, Pinheiro M, Ramos Jr A, Alencar C, Bezerra F, Heukelbach J . Trends in schistosomiasis-related mortality in Brazil, 2000-2011. Int J Parasitol. 2014; 44(14):1055-62. DOI: 10.1016/j.ijpara.2014.07.009. View

2.
ABRANTES W, Antunes C, Lambertucci J . Sonographic features of portal hypertension in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1994; 36(4):355-61. DOI: 10.1590/s0036-46651994000400008. View

3.
De Gottardi A, Rautou P, Schouten J, Rubbia-Brandt L, Leebeek F, Trebicka J . Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019; 4(5):399-411. DOI: 10.1016/S2468-1253(19)30047-0. View

4.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen K . Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60(2):715-35. DOI: 10.1002/hep.27210. View

5.
Huang S, Liu J, Yao J, Zhao J, Wang Y, Ju S . Efficacy and safety of transjugular intrahepatic portosystemic shunt for the treatment of schistosomiasis-induced portal hypertension: a retrospective case series. Eur J Gastroenterol Hepatol. 2022; 34(10):1090-1097. DOI: 10.1097/MEG.0000000000002433. View